Tremfya and Entyvio are two non-anti-TNF biologics for moderate-to-severe ulcerative colitis, each offering meaningful safety advantages over anti-TNFs through very different mechanisms. Tremfya is an IL-23 p19-selective biologic approved for UC in September 2024 based on the QUASAR and ASTRO trials. Entyvio is gut-selective and has been a UC option since 2014, with a head-to-head VARSITY trial showing superiority over adalimumab. Patients weighing these drugs often prioritize long-term safety or seek alternatives to anti-TNF therapy. This guide walks through the tremfya vs entyvio ulcerative colitis comparison.
IL-23 p19 vs Gut-Selective Mechanism
Tremfya (guselkumab) binds the p19 subunit of interleukin-23, selectively blocking the Th17-driving cytokine that fuels UC inflammation. Its immune effects are systemic but narrowly focused on IL-23. Entyvio (vedolizumab) binds the alpha-4-beta-7 integrin, a receptor found almost exclusively on gut-homing lymphocytes. By blocking these immune cells from entering inflamed colonic tissue, Entyvio quiets UC inflammation without meaningfully suppressing the immune system elsewhere. The guselkumab vs vedolizumab UC distinction shapes how each drug performs in different patient populations and their long-term safety profiles.
UC Efficacy Data
Tremfya's UC efficacy rests on QUASAR (induction and maintenance) and ASTRO (fully subcutaneous induction). QUASAR showed clinical remission rates of 23% on guselkumab versus 8% on placebo at week 12, with durable maintenance benefit through week 44. ASTRO demonstrated that patients could achieve meaningful response with SC-only induction. Entyvio's UC efficacy was established in GEMINI-1 and confirmed in VARSITY, where vedolizumab was directly compared with adalimumab in a head-to-head trial. VARSITY showed Entyvio superior to Humira on clinical remission at 52 weeks (31.3% vs 22.5%), establishing vedolizumab as a strong first-line UC biologic. No head-to-head trial has directly compared Tremfya with Entyvio in UC. Indirect comparisons suggest similar clinical remission rates.
Onset of Action
Tremfya produces clinically meaningful response in UC by week 12, based on QUASAR. Entyvio's onset is slower, with meaningful response often not evident until week 10 to 14 and continued improvement through week 26. For UC patients with active symptoms who cannot tolerate a long ramp-up, Tremfya's slightly faster onset is an advantage. For patients in less acute states or those prioritizing the narrowest systemic immune footprint, Entyvio's slower onset is generally manageable with supportive care.
Safety and Infection Risk
Both drugs have favorable safety profiles relative to anti-TNFs. Entyvio's gut-selective action produces very low rates of systemic infection, and its long-term safety data is among the cleanest of any IBD biologic for non-GI infections. A 2024 Swedish registry study flagged a higher rate of serious gastrointestinal infections on vedolizumab compared with anti-TNFs, though overall systemic infection risk was lower. Tremfya's UC safety data from QUASAR and ASTRO has been favorable, consistent with its broader psoriasis and psoriatic arthritis experience. For tremfya vs entyvio UC effectiveness and safety, both drugs are attractive to patients concerned about long-term infection risk on anti-TNFs.
Administration and Dosing
Tremfya offers flexible UC administration. Patients can choose IV induction (200 mg at weeks 0, 4, and 8) or fully subcutaneous induction (400 mg at weeks 0, 4, and 8), per the QUASAR and ASTRO programs. Maintenance is 100 mg SC every 8 weeks or 200 mg SC every 4 weeks. Entyvio starts with three 300 mg IV infusions at weeks 0, 2, and 6, followed by maintenance every 8 weeks. After IV induction, Entyvio patients who respond by week 6 can switch to a 108 mg subcutaneous pen every 2 weeks, according to Takeda's dosing information. For UC patients comparing long-term dosing frequency, Tremfya's every-8-week SC maintenance is less frequent than Entyvio's every-2-week SC maintenance after conversion. Entyvio's IV maintenance (for those who stay on IV) is also every 8 weeks.
Anti-TNF Experienced Patients
For UC patients who have already failed an anti-TNF, both drugs have demonstrated efficacy. QUASAR included biologic-experienced UC patients and showed meaningful response rates on Tremfya. Entyvio also has anti-TNF experienced data, with real-world cohorts showing comparable response rates in this population to other non-TNF options. For patients who have cycled through one anti-TNF and are choosing between Tremfya and Entyvio, trial data supports both drugs as reasonable second-line options. Your GI will weigh prior biologic exposure pattern, current disease severity, and comorbidities when making the recommendation.
Cost and Access
Both Tremfya and Entyvio are priced as branded biologics without biosimilar competition. Insurance coverage varies by plan, and prior authorization is typically required for both drugs in UC. Manufacturer copay assistance programs exist for commercially insured patients on both Tremfya and Entyvio, and patient assistance foundations may help underinsured patients. For UC patients weighing cost, the dosing frequency and administration route can affect indirect costs like infusion center visits, travel time, and missed work. Tremfya's SC maintenance may reduce some of these costs for patients who transition off IV maintenance.
Choosing With Your GI
For a UC patient deciding between Tremfya and Entyvio, both drugs offer meaningful advantages over anti-TNFs. Tremfya tends to win on speed of onset, clinical remission rates at week 12, less frequent SC maintenance, and a fully SC induction option via ASTRO. Entyvio tends to win on the narrowest systemic safety footprint and a head-to-head trial (VARSITY) establishing its superiority over Humira in UC. Your GI will weigh disease severity, prior biologic exposure, comorbidities, and insurance coverage. Before starting either drug, ask how response will be measured after induction (week 12 for Tremfya, week 14 for Entyvio), what to do if symptoms persist, and whether therapeutic drug monitoring will be part of your plan. A log of stool frequency, urgency, blood, and any new symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.